BR0314707A - Conjugado, e, métodos para fabricar um conjugado, e para inibir a transmissão de hiv a uma célula alvo - Google Patents

Conjugado, e, métodos para fabricar um conjugado, e para inibir a transmissão de hiv a uma célula alvo

Info

Publication number
BR0314707A
BR0314707A BR0314707-0A BR0314707A BR0314707A BR 0314707 A BR0314707 A BR 0314707A BR 0314707 A BR0314707 A BR 0314707A BR 0314707 A BR0314707 A BR 0314707A
Authority
BR
Brazil
Prior art keywords
conjugate
methods
hiv
transmission
target cell
Prior art date
Application number
BR0314707-0A
Other languages
English (en)
Inventor
Brian Bray
Myung-Chol Kang
Nicolai Tvermoes
Daniel Kinder
John William Lackey
Huyi Zhang
Original Assignee
Trimeris Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trimeris Inc filed Critical Trimeris Inc
Publication of BR0314707A publication Critical patent/BR0314707A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"CONJUGADO E MéTODOS PARA FABRICAR UM CONJUGADO, E PARA INIBIR A TRANSMISSãO DE HIV A UMA CéLULA ALVO". São fornecidos conjugados que compreendem um polímero tendo operavelmente ligado a ele não menos do que duas moléculas de peptídeo sintético derivadas de gp41 do HIV; métodos para usar estes conjugados para inibir a transmissão de HIV a uma célula alvo pela adição de uma quantidade de eficaz para inibir a infecção da célula pelo vírus; e metodos de produzir os conjugados ligando-se operavelmente cada molécula de peptídeo sintético, por intermédio de uma funcionalidade reativa, ao polímero.
BR0314707-0A 2002-09-27 2003-09-26 Conjugado, e, métodos para fabricar um conjugado, e para inibir a transmissão de hiv a uma célula alvo BR0314707A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41443902P 2002-09-27 2002-09-27
US10/671,282 US7556813B2 (en) 2002-09-27 2003-09-24 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides
PCT/US2003/030285 WO2004029073A2 (en) 2002-09-27 2003-09-26 Conjugates comprised of polymer and hiv gp41-derived peptides and their use in therapy

Publications (1)

Publication Number Publication Date
BR0314707A true BR0314707A (pt) 2005-07-26

Family

ID=32045285

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0314707-0A BR0314707A (pt) 2002-09-27 2003-09-26 Conjugado, e, métodos para fabricar um conjugado, e para inibir a transmissão de hiv a uma célula alvo

Country Status (10)

Country Link
US (2) US7556813B2 (pt)
EP (1) EP1554306A4 (pt)
KR (1) KR20050046780A (pt)
CN (1) CN1684972A (pt)
AU (1) AU2003278937B2 (pt)
BR (1) BR0314707A (pt)
CA (1) CA2497767A1 (pt)
MX (1) MXPA05003036A (pt)
RU (1) RU2317997C2 (pt)
WO (1) WO2004029073A2 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60229677D1 (de) 2001-05-31 2008-12-11 Conjuchem Biotechnologies Inc Langwirkende Fusionspeptidinhibitoren gegen HIV-Infektion
US7556813B2 (en) * 2002-09-27 2009-07-07 Trimeris, Inc. Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides
MXPA06010505A (es) * 2004-03-15 2006-12-19 Nektar Therapeutics Al Corp Composiciones y conjugados, basados en polimeros, de inhibidores de ingreso de vih.
EP1747233A4 (en) * 2004-05-06 2007-04-25 COMPOUNDS FOR SPECIFIC VIRAL TARGET
JP2008534640A (ja) * 2005-04-05 2008-08-28 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー タンパク質の機能部位またはエピトープの遮蔽方法
EP2001508A2 (en) * 2006-03-28 2008-12-17 Novartis Ag Covalently-linked complexes of hiv tat and env proteins
US7936463B2 (en) * 2007-02-05 2011-05-03 Palo Alto Research Center Incorporated Containing analyte in optical cavity structures
CA2724900A1 (en) * 2008-05-28 2009-12-23 New York Blood Center Bifunctional molecules for inhibiting hiv entry
AU2009305577A1 (en) * 2008-10-16 2010-04-22 New York Blood Center Immunoenhancer-linked oligomeric HIV vaccines
WO2010072228A1 (en) * 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
CN102307588A (zh) * 2009-02-09 2012-01-04 纽约血库公司 用于治疗或预防hiv感染的三聚体hiv融合抑制剂
US8293100B2 (en) 2009-03-13 2012-10-23 Terrasep, Llc Methods and apparatus for centrifugal liquid chromatography
AU2011248279A1 (en) 2010-05-03 2012-11-01 New York Blood Center, Inc. Bifunctional molecules for inactivating HIV and blocking HIV
WO2013127299A1 (zh) * 2012-02-28 2013-09-06 中国人民解放军军事医学科学院毒物药物研究所 用于抑制hiv的多肽及其作用靶点

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902502A (en) * 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
NZ254640A (en) 1992-07-20 1997-04-24 Univ Duke Hiv protein fragments of transmembrane glycoprotein gp41 (dp-107) with antiviral activity and their use
US5464933A (en) * 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
JPH11507632A (ja) * 1995-06-07 1999-07-06 トリメリス，インコーポレーテッド 併用療法を用いたｈｉｖおよび他のウイルス感染の治療
US5767078A (en) 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
US6258774B1 (en) 1998-03-19 2001-07-10 University Of Medicine And Dentistry Of New Jersey Carrier for in vivo delivery of a therapeutic agent
US6281331B1 (en) * 1998-03-23 2001-08-28 Trimeris, Inc. Methods and compositions for peptide synthesis
US6656906B1 (en) * 1998-05-20 2003-12-02 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6258782B1 (en) 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
CN1351611A (zh) * 1999-05-17 2002-05-29 康久化学公司 病毒感染的长效融合肽抑制剂
US7556813B2 (en) * 2002-09-27 2009-07-07 Trimeris, Inc. Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides

Also Published As

Publication number Publication date
EP1554306A2 (en) 2005-07-20
US20100016225A1 (en) 2010-01-21
RU2317997C2 (ru) 2008-02-27
MXPA05003036A (es) 2005-05-27
US7556813B2 (en) 2009-07-07
US20040122214A1 (en) 2004-06-24
WO2004029073A2 (en) 2004-04-08
AU2003278937A1 (en) 2004-04-19
CA2497767A1 (en) 2004-04-08
RU2005112729A (ru) 2005-09-20
EP1554306A4 (en) 2009-01-21
WO2004029073A3 (en) 2004-08-12
CN1684972A (zh) 2005-10-19
AU2003278937B2 (en) 2009-12-03
KR20050046780A (ko) 2005-05-18

Similar Documents

Publication Publication Date Title
BR0314707A (pt) Conjugado, e, métodos para fabricar um conjugado, e para inibir a transmissão de hiv a uma célula alvo
BRPI0417341A (pt) fator ix glicopeguilado
BRPI0412671A (pt) conjugados de um polìmero e uma proteìna ligados por um grupo de ligação de oxima
BRPI0611872B8 (pt) reagente polimérico, conjugado, método para preparação de um conjugado e composição farmacêutica
ECSP034855A (es) Administracion pulmonar de insulina quimicamente modificada
WO2007113223A3 (en) Immunogenic composition
SG155777A1 (en) Glycopegylation methods and proteins/peptides produced by the methods
DE50014571D1 (de) Träger-pharmaka-konjugate
BR0109973A (pt) Composição de polìmero para tubulações
CO6480930A2 (es) Composiciones y procedimientos para preparar composiciones inmunogénicas de conjugado de polisacárido capsular de serotipo 5 y 8 de staphylococcus aureus.
BR0208126A (pt) Conjugados de ingrediente ativo de has
BR0111457A (pt) Derivados de acilfeniluréia, processos para a sua preparação e sua aplicação como medicamentos
BRPI0612669B8 (pt) composição imunogênica, vacina, composição, e composição liofilizada
EA200400067A1 (ru) Конъюгаты гксф
AR069903A1 (es) Conjugado anticuerpo- molecula asociada dirigidos a la proteina tirosina quinasa 7 (ptk 7), composicion farmaceutica que lo comprende, acido nucleico, factor de expresion y celula huesped relacionados y su uso para preparar un medicamento util para el tratamiento o prevencion de cancer
AR066476A1 (es) Anticuerpos anti-muc16 disenados con cisteina y conjugaods de anticuerpos y farmacos
BR0309868A (pt) Conjugados de derivados de caliqueamicina - veìculo
DE60138641D1 (de) Herstellung von mikrokügelchen
BR0209689A (pt) Uso de fragmento de hmg como agente anti-inflamatório
BRPI0614839A2 (pt) fator vii e fator viia glicopeguilados
BRPI0505302A (pt) processo de toner
NO20015584D0 (no) Lantidsvarende insulintrofiske peptider
BR0112676A (pt) Bifenilcarboxamidas
ATE409048T1 (de) Pharmazeutisch aktive oligosaccharid-conjugate
BR0116169A (pt) Composto, composição farmacêutica que compreende esse composto, processo para a preparação de uma composição farmacêutica, utilização dos compostos, processo para o tratamento profilático ou terapêutico de diabetes do tipo ii e processo para a preparação do composto.

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE(S).

B08G Application fees: restoration [chapter 8.7 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 10A, 11A E 12A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.